A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Disease Sites:

Not Available

Staging:

Phase II

Age Group:

Both

Therapies:

Mol. targeted/Immunotherapy/Biologics, Therapy (NOS)

Drugs:

Axatilimab, Corticosteroids, Ruxolitinib

Principal Investigator(s):

Kitko, Carrie

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

04-22-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTCTT24000

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available